These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 15191332

  • 1. Pharmacological approach to the treatment of acromegaly.
    Ezzat S.
    Neurosurg Focus; 2004 Apr 15; 16(4):E3. PubMed ID: 15191332
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological management of acromegaly: a current perspective.
    Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR.
    Neurosurg Focus; 2010 Oct 15; 29(4):E14. PubMed ID: 20887124
    [Abstract] [Full Text] [Related]

  • 3. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 4. [Optimization of the medical treatment for acromegaly].
    Díez JJ, Iglesias P.
    Med Clin (Barc); 2013 Apr 20; 140(8):360-5. PubMed ID: 23103101
    [Abstract] [Full Text] [Related]

  • 5. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ.
    J Clin Endocrinol Metab; 2012 Apr 20; 97(4):1187-93. PubMed ID: 22278424
    [Abstract] [Full Text] [Related]

  • 6. Cabergoline in acromegaly.
    Kuhn E, Chanson P.
    Pituitary; 2017 Feb 20; 20(1):121-128. PubMed ID: 28025719
    [Abstract] [Full Text] [Related]

  • 7. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug 20; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H, Shimatsu A, Okayama A, Sato T.
    Endocr J; 2020 Feb 28; 67(2):201-210. PubMed ID: 31723069
    [Abstract] [Full Text] [Related]

  • 9. Medical therapy of acromegaly in Turkey.
    Celik O, Kadioglu P.
    J Endocrinol Invest; 2010 Sep 28; 33(8):592-8. PubMed ID: 20930498
    [Abstract] [Full Text] [Related]

  • 10. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug 28; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 11. New perspectives in the medical treatment of acromegaly.
    Colao A, Pivonello R, Auriemma RS, Galdiero M, Guerra E, Milone F, De Leo M, Lombardi G.
    J Endocrinol Invest; 2005 Aug 28; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin analogs in medical treatment of acromegaly.
    Racine MS, Barkan AL.
    Endocrine; 2003 Apr 28; 20(3):271-8. PubMed ID: 12721507
    [Abstract] [Full Text] [Related]

  • 13. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR, Romijn JA, Pereira AM, Roelfsema F.
    Expert Opin Pharmacother; 2005 Nov 28; 6(14):2393-405. PubMed ID: 16259571
    [Abstract] [Full Text] [Related]

  • 14. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M, Soto A, Venegas E, Vilchez R, Blanco C, Cordido F, Lucas T, Marazuela M, Casany R, Cuatrecasas G, Fajardo C, Gálvez MÁ, Maraver S, Martín T, Romero E, Paja M, Picó A, Bernabeu I, Resmini E, ACROCOMB study group.
    Endocrinol Nutr; 2016 Oct 28; 63(8):397-408. PubMed ID: 27448708
    [Abstract] [Full Text] [Related]

  • 15. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H.
    J Clin Endocrinol Metab; 2005 Oct 28; 90(10):5627-31. PubMed ID: 16046586
    [Abstract] [Full Text] [Related]

  • 16. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr 28; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 17. [Therapeutic management of acromegaly].
    Metzner C, Hadziselimovic S, Grafe I, Nawroth P, Kasperk C.
    Med Klin (Munich); 2006 Jan 15; 101(1):15-23. PubMed ID: 16418810
    [Abstract] [Full Text] [Related]

  • 18. The role of primary pharmacological therapy in acromegaly.
    Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, Gadelha M, Abreu A, Mercado M.
    Pituitary; 2014 Jan 15; 17 Suppl 1(Suppl 1):S4-10. PubMed ID: 24166706
    [Abstract] [Full Text] [Related]

  • 19. Role of medical therapy in the management of acromegaly.
    Vance ML, Laws ER.
    Neurosurgery; 2005 May 15; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [Abstract] [Full Text] [Related]

  • 20. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
    Chanson P.
    Neuroendocrinology; 2016 May 15; 103(1):50-8. PubMed ID: 25677539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.